Phosphorus-32 & Legacy Radionuclide Therapies

Quick Answer

Phosphorus-32 is a pure beta emitter (no gamma) historically used to control myeloproliferative neoplasms — chiefly polycythemia vera — as sodium phosphate (systemic), and, as chromic phosphate colloid, for intracavitary treatment of malignant effusions. It is highly effective and convenient but now second/third-line, because P-32 (like other alkylating-type control) raises the long-term risk of leukemic transformation; it is reserved for older or poorly compliant patients where that risk matters less. Its pure-beta emission means no imaging, easy shielding (low-Z, then lead for bremsstrahlung), and body-fluid precautions.

Background & Mechanism

• Sodium phosphate-32 (systemic): phosphate is incorporated into rapidly dividing cells and bone/marrow, delivering β dose that suppresses marrow overproduction in PV (and, historically, essential thrombocythemia).
• Chromic phosphate-32 colloid (intracavitary): a non-absorbable colloid instilled into the peritoneal/pleural space to irradiate serosal surfaces for malignant effusions (largely historical). Chromic phosphate is colloidal (stays in the cavity); sodium phosphate is soluble (systemic) — never interchange them.

Indications (contemporary context)

• Polycythemia vera — durable hematologic control, especially in older patients or where oral cytoreduction (hydroxyurea) and phlebotomy are impractical/poorly tolerated.
• Essential thrombocythemia — historical.
• Malignant pleural/peritoneal effusions — chromic phosphate, largely superseded.
• Radiosynovectomy in some regions historically used chromic-P-32 (now Y-90/Re-186/Er-169).

Why It Is Now Second-Line

Long-term data associate P-32 (and alkylating agents) with increased leukemic/myelodysplastic transformation versus phlebotomy ± hydroxyurea, so guidelines favor phlebotomy, aspirin, and hydroxyurea/interferon/JAK inhibitors first. P-32 remains a legitimate option when compliance, age, or logistics outweigh the transformation risk.

Administration & Practicalities

• Confirm the diagnosis and counts; systemic P-32 is given IV (sodium phosphate).
• Pure beta → no post-therapy imaging; shield with low-Z material first (acrylic) then lead to limit bremsstrahlung.
• Body-fluid/hygiene precautions (renal and GI excretion of systemic P-32); intracavitary colloid stays largely in the cavity but requires leak-free instillation.

Toxicity

• Myelosuppression (the therapeutic effect and the dose-limiter).
• Long-term leukemic/MDS transformation risk — the reason for its second-line status.

Common Pitfalls

• Confusing sodium phosphate (soluble, systemic) with chromic phosphate (colloid, intracavitary) — different agents, different routes.
• Shielding pure-beta P-32 with lead alone → bremsstrahlung (use acrylic first).
• Overlooking the leukemogenic-risk rationale for reserving it to older/noncompliant patients.

Board Pearls

Phosphorus-32 is a pure beta emitter used historically for polycythemia vera as soluble sodium phosphate (systemic) and, as chromic phosphate colloid, for intracavitary malignant effusions. It is now second/third-line because it raises long-term leukemic/MDS transformation risk — reserved for older or poorly compliant patients where that risk is less pivotal.

Sodium phosphate is soluble/systemic; chromic phosphate is a colloid that stays in the cavity — never interchange them. Being pure beta, P-32 gives no imaging, and must be shielded low-Z (acrylic) first, then lead to avoid bremsstrahlung.

First-line PV management is phlebotomy, aspirin, and hydroxyurea/interferon/JAK inhibitors; P-32's durable control still suits selected patients. Myelosuppression is both the therapeutic mechanism and the dose-limiter. Historic chromic-P-32 radiosynovectomy has been replaced by Y-90/Re-186/Er-169.

Related Pages

• Physics: radiation biology & protection (beta/bremsstrahlung shielding); therapy: radiosynovectomy, bone-pain palliation.

Figure / Diagram Suggestions

• A sodium (soluble/systemic) vs chromic (colloid/intracavitary) phosphate comparison.
• A PV therapy ladder (phlebotomy/HU/interferon → P-32 in selected patients).

Self-Check